We analysed the outcome of a second allogeneic haematopoietic stem cell transplant (alloHSCT) in 162 patients reported to the European Society for Blood and Marrow Transplantation between 1998 and 2009. Donor origin was a sibling in 110 and an unrelated donor in 52 transplants, respectively. The stem cell source was bone marrow in 31% and peripheral blood in 69% of transplants. The same donor as for the first alloHSCT was used in 81% of transplants whereas a change in the choice of stem cell source was reported in 56% of patients, mainly from bone marrow to peripheral blood. Neutrophil and platelet engraftment occurred in 85% and 72% of patients, after a median time of 15 and 17 days, respectively. Grade II-IV acute graft-versus-host disease (GVHD) and chronic GVHD occurred in 21% and 37% of patients, respectively. Graft failure (GF) occurred in 42 patients (26%). After a median follow-up of 3·5 years, the 5-year overall survival (OS) was 60·7%. In multivariate analysis, the only factor significantly associated with a better outcome was a Karnofsky/Lansky score ≥80 (higher OS). We conclude that a second alloHSCT is feasible rescue option for GF in SAA, with a successful outcome in 60% of cases.
Second allogeneic stem cell transplant for aplastic anaemia : a retrospective study by the severe aplastic anaemia working party of the European society for blood and marrow transplantation / S. Cesaro, R.P. de Latour, G. Tridello, M. Pillon, K. Carlson, F. Fagioli, J. Jouet, M.B..C. Koh, I.S. Panizzolo, S. Kyrcz-Krzemien, J. Maertens, A. Rambaldi, B. Strahm, D. Blaise, A. Maschan, J. Marsh, C. Dufour. - In: BRITISH JOURNAL OF HAEMATOLOGY. - ISSN 0007-1048. - 171:4(2015 Nov), pp. 606-614.
Second allogeneic stem cell transplant for aplastic anaemia : a retrospective study by the severe aplastic anaemia working party of the European society for blood and marrow transplantation
A. Rambaldi;
2015
Abstract
We analysed the outcome of a second allogeneic haematopoietic stem cell transplant (alloHSCT) in 162 patients reported to the European Society for Blood and Marrow Transplantation between 1998 and 2009. Donor origin was a sibling in 110 and an unrelated donor in 52 transplants, respectively. The stem cell source was bone marrow in 31% and peripheral blood in 69% of transplants. The same donor as for the first alloHSCT was used in 81% of transplants whereas a change in the choice of stem cell source was reported in 56% of patients, mainly from bone marrow to peripheral blood. Neutrophil and platelet engraftment occurred in 85% and 72% of patients, after a median time of 15 and 17 days, respectively. Grade II-IV acute graft-versus-host disease (GVHD) and chronic GVHD occurred in 21% and 37% of patients, respectively. Graft failure (GF) occurred in 42 patients (26%). After a median follow-up of 3·5 years, the 5-year overall survival (OS) was 60·7%. In multivariate analysis, the only factor significantly associated with a better outcome was a Karnofsky/Lansky score ≥80 (higher OS). We conclude that a second alloHSCT is feasible rescue option for GF in SAA, with a successful outcome in 60% of cases.File | Dimensione | Formato | |
---|---|---|---|
Cesaro_et_al-2015-British_Journal_of_Haematology.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
120.71 kB
Formato
Adobe PDF
|
120.71 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.